RxDoctor Payments Data

Nicole Nahmod, PA

Surgical · Charlottesville, VANPI 1548839467

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $517 and has fallen 65.1% since, to $181 in 2024.

$1,143in general payments, 2019–2025

Across 60 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$259
  • AbbVie$166
  • Biohaven Pharmaceutical Holding Company Ltd.$153
  • Amgen$95
  • GRT US Holding, Inc.$73
  • Lilly USA, LLC$67
  • plus $331 from 10 others

What the payments were for

  • Food & beverage$1,143100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,143 in reported general payments places this provider in the 75th percentile of 201 surgical providers in Virginia.

See all surgical providers in Virginia

Medicare billing

Part B allowed, 2024
$105,604
Medicare patients
410
Services billed
2,048

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine125$31,850
Xtampza ErOxycodone Myristate57$31,401
BelbucaBuprenorphine Hcl27$19,423
OxycontinOxycodone Hcl32$14,059
Pregabalin330$8,837
NucyntaTapentadol Hcl11$8,605
Morphine Sulfate ErMorphine Sulfate324$8,237
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen346$6,572
Fentanyl56$6,059
SavellaMilnacipran Hcl12$5,752
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen268$5,214
Diclofenac Sodium80$3,565
Gabapentin284$3,528
Tramadol Hcl349$3,159
Oxycodone Hcl219$3,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta$259$59,42895 claims
Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Morphine Sulfate$21$35,550271 claims
AbbVieSavella$166$5,75212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 201 surgical providers in Virginia.

Other surgical in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →